FPGEE 2026 Practice Exam for NABP – The Complete All-in-One Guide to Exam Success!

The correct choice is the FDA, as this organization is responsible for regulating and overseeing the safety and efficacy of drugs and medical devices in the United States. The FDA evaluates and determines which products may not be considered safe or effective for extemporaneous preparation, often compiling a list of drugs that should not be compounded due to concerns about their safety, efficacy, or the potential risks they present to patients.

For example, if certain formulations or active pharmaceutical ingredients have been associated with significant side effects or lack adequate clinical evidence supporting their use, the FDA may issue guidelines or lists indicating that these should not be used for compounding. This is important to ensure that pharmacists provide safe and effective treatments to patients, aligning with best practices in pharmaceutical care.

Meanwhile, other organizations such as the CDC, NABP, and WHO have distinct roles in public health, pharmacy practice, and global health standards, but they do not specifically determine the safety and efficacy of products for extemporaneous preparation in the same way the FDA does.